Siegberg R, Ylöstalo P, Laatikainen T, Pelkonen R, Stenman U H
Arch Gynecol. 1987;240(2):67-73. doi: 10.1007/BF02134038.
In a double-blind cross-over study, 24 hyperandrogenic women were treated for three months at a time with either spironolactone 100 mg or placebo daily from the 5th to the 21st days of the menstrual cycle. Spironolactone had a slight but statistically insignificant effect on hirsutism when compared with placebo. Slightly more regular menstruation and better follicular growth was noted during spironolactone treatment. Ovulation (defined as a day 21 serum progesterone level of more than 10 nmol/l) occurred in only 12% of spironolactone cycles, as against 28% of placebo cycles. Spotting occurred in one-third of the spironolactone cycles. No significant differences were found between spironolactone and placebo cycles in serum levels of LH, FSH, prolactin, estradiol, progesterone, androstenedione, total testosterone, sex-hormone binding globulin (SHBG), unbound testosterone, dehydroepiandrosterone sulphate (DHEAS), cortisol, potassium and sodium. The average ovarian volume was 13.0 (5.7-21.8) cm3, and no significant differences were found between treatment and placebo cycles. No significant effect of spironolactone could be demonstrated on androgen secretion and the incidence of ovulation.
在一项双盲交叉研究中，24名高雄激素血症女性在月经周期的第5天至第21天，每次接受为期三个月的治疗，每天服用100毫克螺内酯或安慰剂。与安慰剂相比，螺内酯对多毛症有轻微但无统计学意义的影响。在螺内酯治疗期间，月经周期略有规律，卵泡生长情况较好。在接受螺内酯治疗的周期中，只有12%出现排卵（定义为第21天血清孕酮水平超过10 nmol/l），而安慰剂周期的排卵率为28%。在三分之一的螺内酯治疗周期中出现点滴出血。在血清促黄体生成素（LH）、促卵泡生成素（FSH）、催乳素、雌二醇、孕酮、雄烯二酮、总睾酮、性激素结合球蛋白（SHBG）、游离睾酮、硫酸脱氢表雄酮（DHEAS）、皮质醇、钾和钠水平方面，螺内酯治疗周期与安慰剂周期之间未发现显著差异。平均卵巢体积为13.0（5.7 - 21.8）cm³，治疗周期与安慰剂周期之间未发现显著差异。未证明螺内酯对雄激素分泌和排卵发生率有显著影响。
